|

Ifinatamab deruxtecan (I-DXd) Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: DS-7300a, MK-2400

Pipeline

Phase 1/2: 3

Top Sponsors

  • Merck Sharp & Dohme LLC2
  • Daiichi Sankyo1

Indications

  • Cancer3
  • Lung Cancer2
  • Malignant Solid Tumor1
  • Carcinoma, Non-Small-Cell Lung1
  • Advanced Solid Tumor1

Gilbert, Arizona1 trial

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Banner MD Anderson Cancer Center ( Site 0001)

Phase 1/2

Los Angeles, California1 trial

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Cedars-Sinai Medical Center- Samuel Oschin Comprehensive Cancer Institute

Phase 1/2

Aurora, Colorado1 trial

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

University of Colorado Anschutz Medical Campus ( Site 1110)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.